imatinib mesylate has been researched along with Leukemia, Acute Monocytic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aichele, O; Brümmendorf, T; Denzlinger, C; Kanz, L; Kröber, SM; Schittenhelm, M | 1 |
| Brizard, A; Brizard, F; Cividin, M; Guilhot, F; Renaud, M; Sorel, N | 1 |
2 other study(ies) available for imatinib mesylate and Leukemia, Acute Monocytic
| Article | Year |
|---|---|
Complete remission of third recurrence of acute myeloid leukemia after treatment with imatinib (STI-571).
Topics: Aged; Antineoplastic Agents; Benzamides; Bone Marrow; Disease Progression; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia, Monocytic, Acute; Male; Neoplasm Recurrence, Local; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Remission Induction; Salvage Therapy | 2003 |
p190(BCR-ABL) rearrangement as a secondary change in a case of acute myelo-monocytic leukemia with inv(16)(p13q22).
Topics: Adult; Antineoplastic Agents; Benzamides; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Cytogenetics; Female; Fusion Proteins, bcr-abl; Gene Rearrangement; Humans; Imatinib Mesylate; Leukemia, Monocytic, Acute; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Salvage Therapy; Translocation, Genetic | 2004 |